Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Clinically relevant transmitted drug resistance to first line antiretroviral drugs and implications for recommendations.

  • Monge Corella, Susana
  • Guillot, Vicente
  • Alvarez, Marta
  • Chueca, Natalia
  • Stella, Natalia
  • Peña, Alejandro
  • Delgado, Rafael
  • Córdoba, Juan
  • Aguilera, Antonio
  • Vidal, Carmen
  • García, Federico
The aim was to analyse trends in clinically relevant resistance to first-line antiretroviral drugs in Spain, applying the Stanford algorithm, and to compare these results with reported Transmitted Drug Resistance (TDR) defined by the 2009 update of the WHO SDRM list. We analysed 2781 sequences from ARV naive patients of the CoRIS cohort (Spain) between 2007-2011. Using the Stanford algorithm "Low-level resistance", "Intermediate resistance" and "High-level resistance" categories were considered as "Resistant". 70% of the TDR found using the WHO list were relevant for first-line treatment according to the Stanford algorithm. A total of 188 patients showed clinically relevant resistance to first-line ARVs [6.8% (95%Confidence Interval: 5.8-7.7)], and 221 harbored TDR using the WHO list [7.9% (6.9-9.0)]. Differences were due to a lower prevalence in clinically relevant resistance for NRTIs [2.3% (1.8-2.9) vs. 3.6% (2.9-4.3) by the WHO list] and PIs [0.8% (0.4-1.1) vs. 1.7% (1.2-2.2)], while it was higher for NNRTIs [4.6% (3.8-5.3) vs. 3.7% (3.0-4.7)]. While TDR remained stable throughout the study period, clinically relevant resistance to first line drugs showed a significant trend to a decline (p = 0.02). Prevalence of clinically relevant resistance to first line ARVs in Spain is decreasing, and lower than the one expected looking at TDR using the WHO list. Resistance to first-line PIs falls below 1%, so the recommendation of screening for TDR in the protease gene should be questioned in our setting. Cost-effectiveness studies need to be carried out to inform evidence-based recommendations.
Repisalud
Publicación Artículo científico (JournalArticle)

HIV-1 envelope glycoproteins isolated from Viremic Non-Progressor individuals are fully functional and cytopathic

  • Cabrera-Rodríguez, Romina
  • Hebmann, Veronique
  • Marfil, Silvia
  • Pernas, Maria
  • Marrero-Hernández, Sara
  • Cabrera, Cecilia
  • Urrea, Víctor
  • Casado, Concepcion
  • Olivares, Isabel
  • Márquez-Arce, Daniel
  • Pérez-Yanes, Silvia
  • Estévez-Herrera, Judith
  • Clotet, Bonaventura
  • Espert, Lucile
  • Lopez-Galindez, Luis Cecilio
  • Biard-Piechaczyk, Martine
  • Valenzuela-Fernández, Agustín
  • Blanco, Julià
In untreated HIV-1-infected individuals, viremia is positively associated with disease progression. However, some viremic non progressors (VNPs) individuals show paradoxical high CD4+ T cell counts. HIV-1 envelope glycoprotein complex (Env) is a major cytopathic determinant in viral replication; therefore, we have deeply characterized Env function in this rare clinical phenotype. Full-length Env clones isolated from individuals with Viral Load (VL) > 10,000 copies/mL classified as VNPs (n = 15) or rapid progressors (RPs, n = 17) were geno- and phenotypically analyzed by determining diversity, expression, CD4 binding/signaling, fusogenicity, infectivity and autophagy induction. Selected Env clones from VNPs and RPs (n = 32) showed similar expression, fusion and infection abilities. Env clones from both groups showed similar affinity for CD4 during cell-to-cell transmission and consistently induced similar levels of CD4 signaling, measured by α-tubulin acetylation. Moreover, we demonstrate for the first time that primary Env clones from VNP and RP induce autophagy in uninfected cells and that this feature correlated with fusogenic capacity but was unrelated to disease progression. In conclusion, our data suggest that Env clones from VNP individuals are fully functional. Therefore, the paradoxical CD4+ T cell count stability coexisting with high levels of viral replication is unrelated to Env function.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Clinically Relevant Transmitted Drug Resistance to First Line Antiretroviral Drugs and Implications for Recommendations

  • Monge, Susana
  • Guillot, Vicente
  • Álvarez, Marta
  • Chueca, Natalia
  • Stella, Natalia
  • Peña, Alejandro
  • Delgado, Rafael
  • Córdoba, Juan
  • Aguilera Guirao, Antonio
  • Vidal, Carmen
  • García, Federico
  • CoRIS
Background: The aim was to analyse trends in clinically relevant resistance to first-line antiretroviral drugs in Spain, applying the Stanford algorithm, and to compare these results with reported Transmitted Drug Resistance (TDR) defined by the 2009 update of the WHO SDRM list. Methods: We analysed 2781 sequences from ARV naive patients of the CoRIS cohort (Spain) between 2007–2011. Using the Stanford algorithm “Low-level resistance”, “Intermediate resistance” and “High-level resistance” categories were considered as “Resistant”. Results: 70% of the TDR found using the WHO list were relevant for first-line treatment according to the Stanford algorithm. A total of 188 patients showed clinically relevant resistance to first-line ARVs [6.8% (95%Confidence Interval: 5.8–7.7)], and 221 harbored TDR using the WHO list [7.9% (6.9–9.0)]. Differences were due to a lower prevalence in clinically relevant resistance for NRTIs [2.3% (1.8–2.9) vs. 3.6% (2.9–4.3) by the WHO list] and PIs [0.8% (0.4–1.1) vs. 1.7% (1.2–2.2)], while it was higher for NNRTIs [4.6% (3.8–5.3) vs. 3.7% (3.0–4.7)]. While TDR remained stable throughout the study period, clinically relevant resistance to first line drugs showed a significant trend to a decline (p = 0.02). Conclusions: Prevalence of clinically relevant resistance to first line ARVs in Spain is decreasing, and lower than the one expected looking at TDR using the WHO list. Resistance to first-line PIs falls below 1%, so the recommendation of screening for TDR in the protease gene should be questioned in our setting. Cost-effectiveness studies need to be carried out to inform evidence-based recommendations.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lamb–Shaffer syndrome: 20 Spanish patients and literature review expands the view of neurodevelopmental disorders caused by SOX5 haploinsufficiency

  • Tenorio-Castaño, Jair Antonio
  • Gómez, Á.S.A.
  • Coronado, M.
  • Rodríguez-Martín, Pilar
  • Parra, A.
  • Pascual, P.
  • Cazalla, M.
  • Gallego, Natalia
  • Arias, Pedro
  • Morales, Aixa V.
  • Nevado, Julian
  • Lapunzina, Pablo
Lamb–Shaffer Syndrome (LSS; OMIM #616803; ORPHA #313892; ORPHA #313884) is an infrequent genetic disorder that affects multiple aspects of human development especially those related to the development of the nervous system. LSS is caused by variants in the SOX5 gene. At the molecular level, SOX5 gene encodes for a transcription factor containing a High Mobility Group (HMG) DNA-Binding domain with relevant functions in brain development in different vertebrate species. Clinical features of Lamb–Shaffer syndrome may include intellectual disability, delayed speech and language development, attention deficits, hyperactivity, autism spectrum disorder, visual problems and seizures. Additionally, patients with the syndrome may present distinct facial dimorphism such as a wide mouth with full lips, small chin, broad nasal bridge, and deep-set eyes. Other physical features that have been reported in some patients include short stature, scoliosis, and joint hypermobility. Here, we report the clinical and molecular characterization of a Spanish LSS cohort of new 20 patients and review all the patients published so far which amount for 111 patients. The most frequent features included developmental delay, intellectual disability, visual problems, poor speech development and facial dysmorphic features. Strikingly, pain insensitivity and hypermetropia seems to be more frequent than previously reported, based on the frequency seen in the Spanish cohort. Eighty-three variants have been reported so far, single nucleotide variants (SNV) and copy number variants represent 47% and 53%, respectively, from the total of variants reported. Similarly to previous reports, the majority of the SNVs variants of the novel patients reported herein fall in the HMG domain of the protein. However, new variants, affecting other functional domains, were also detected. In conclusion, LLS is a rare genetic disorder mostly characterized by a wide range of developmental and neurological symptoms. Early diagnosis would allow to start of care programs, clinical follow up, prospective studies and appropriate genetic counseling, to promote clinical and social improvement to have profound lifelong benefits for patients and their families. Further research is needed to better understand the underlying mechanisms of the syndrome related to SOX5 haploinsufficiency., European Regional Development Fund;Instituto de Salud Carlos III, Grant/AwardNumbers: PI20/01053, PMP22/00049,PMP21/00063, Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Snijders Blok–Campeau Syndrome: Description of 20 additional individuals with variants in CHD3 and literature review

  • Pascual, Patricia
  • Tenorio-Castano, Jair
  • Mignot, Cyril
  • Afenjar, Alexandra
  • Arias, Pedro
  • Gallego-Zazo, Natalia
  • Parra, Alejandro
  • Miranda, Lucia
  • Cazalla, Mario
  • Silván, Cristina
  • Heron, Delphine
  • Keren, Boris
  • Popa, Ioana
  • Palomares, María
  • Rikeros, Emi
  • Ramos, Feliciano J.
  • Almoguera, Berta
  • Ayuso, Carmen
  • Swafiri, Saoud Tahsin
  • Barbero, Ana Isabel Sánchez
  • Srinivasan, Varunvenkat M.
  • Gowda, Vykuntaraju K.
  • Morleo, Manuela
  • Nigro, Vicenzo
  • D’Arrigo, Stefano
  • Ciaccio, Claudia
  • Martin Mesa, Carmen
  • Paumard, Beatriz
  • Guillen, Gema
  • Anton, Ana Teresa Serrano
  • Jimenez, Marta Domínguez
  • Seidel, Veronica
  • Suárez, Julia
  • Cormier-Daire, Valerie
  • Consortium, The SOGRI
  • Nevado, Julián
  • Lapunzina, Pablo
Snijders Blok–Campeau syndrome (SNIBCPS, OMIM# 618205) is an extremely infrequent disease with only approximately 60 cases reported so far. SNIBCPS belongs to the group of neurodevelopmental disorders (NDDs). Clinical features of patients with SNIBCPS include global developmental delay, intellectual disability, speech and language difficulties and behavioral disorders like autism spectrum disorder. In addition, patients with SNIBCPS exhibit typical dysmorphic features including macrocephaly, hypertelorism, sparse eyebrows, broad forehead, prominent nose and pointed chin. The severity of the neurological effects as well as the presence of other features is variable among subjects. SNIBCPS is caused likely by pathogenic and pathogenic variants in CHD3 (Chromodomain Helicase DNA Binding Protein 3), which seems to be involved in chromatin remodeling by deacetylating histones. Here, we report 20 additional patients with clinical features compatible with SNIBCPS from 17 unrelated families with confirmed likely pathogenic/pathogenic variants in CHD3. Patients were analyzed by whole exome sequencing and segregation studies were performed by Sanger sequencing. Patients in this study showed different pathogenic variants affecting several functional domains of the protein. Additionally, none of the variants described here were reported in control population databases, and most computational predictors suggest that they are deleterious. The most common clinical features of the whole cohort of patients are global developmental delay (98%) and speech disorder/delay (92%). Other frequent features (51–74%) include intellectual disability, hypotonia, hypertelorism, abnormality of vision, macrocephaly and prominent forehead, among others. This study expands the number of individuals with confirmed SNIBCPS due to pathogenic or likely pathogenic variants in CHD3. Furthermore, we add evidence of the importance of the application of massive parallel sequencing for NDD patients for whom the clinical diagnosis might be challenging and where deep phenotyping is extremely useful to accurately manage and follow up the patients.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Direct recycling of 3D-printed Co-YDZ catalysts for ethanol steam reforming

  • Razavi, Seyed Ali
  • Fargas, Gemma
  • Serrano, Isabel
  • Laguna-Bercero, Miguel Ángel
  • Vilella, Tània
  • Llanes, Luis
  • Rodríguez, Daniel
  • Ginebra, Maria-Pau
  • Llorca, Jordi
  • Morales, Miguel
Additive manufacturing enhances the catalyst performance via hierarchical design. To address environmental and resource concerns, this work aims to fabricate directly recycled 3D-printed monoliths using Direct-Ink Writing (DIW) from 100 % recovered cobalt-zirconia powders. Virgin cobalt-zirconia monoliths were firstly fabricated by DIW of 3.0–7.0 wt% Co-enriched hydrogel-based ceramic inks, followed by calcination at 600°C in a single thermal treatment. After testing the catalytic performance of monoliths in ethanol steam reforming, 3D-printed cobalt-zirconia monoliths were fragmented and subjected to subsequent milling and sieving steps to recover composite cobalt-zirconia powders with the appropriate properties for reuse in DIW. The recovered powders, inks and monoliths were microstructurally, rheologically and catalytically characterized, and then compared to catalysts constituted by virgin materials. The rheology properties of inks for the recycled and virgin monoliths presented an appropriate printability. Furthermore, the catalytic performance of recycled monoliths was close to that exhibited by virgin catalysts. This study demonstrates the feasibility of directly recycling fully 3D-printed catalysts, potentially reducing the environmental impact with a circular production model to enhance sustainability in the catalyst industry.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Modulation of the autophagic pathway inhibits HIV-1 infection in human lymphoid tissue cultured ex vivo

  • Pedreño-López, Sònia|||0000-0002-1919-3530
  • García Rodríguez, Elisabet
  • Guerrero, Dolores
  • Gomez, Elisabet|||0000-0002-9779-5940
  • Molina Mateu, Laura
  • Orera Pérez, Fernando
  • Senserrich, Jordi|||0000-0002-8021-1718
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Cabrera Navarro, Cecilia|||0000-0002-9941-6828
A complex link exists between HIV-1 and autophagy, and discordant results have been reported in different in vitro models regarding the way HIV and autophagy modulate each other. Despite this, there is very limited knowledge about the interplay between HIV and autophagy in vivo in lymphoid tissue, due in part by the lack of cell models that recapitulate the in vivo setting. Here, we evaluate the interrelationship between HIV and autophagy using human ex vivo lymphoid tissue cultures as an HIV infection model. Our results showed that human lymphoid aggregated cultures (HLACs) from tonsillar tissue displayed fully functional autophagic activity. In this system, HIV infection resulted in an increase in autophagy. Notably, we observed that both, autophagy-enhancing (rapamycin) or blocking drugs (3-methyladenine, chloroquine and bafilomycin), were able to decrease HIV-DNA levels and HIV replication. Therefore, efficient HIV-1 replication requires a fine-tuned level of autophagy, so modifications of this balance will have a negative impact on its replication. Therefore, targeting the autophagic pathway could be a new therapeutic approach to be explored to treat HIV-1 infection. Ex vivo cultures of human lymphoid tissue are a suitable model to obtain further insights into HIV and its intricate relationship with autophagy.